Zobrazeno 1 - 10
of 527
pro vyhledávání: '"Chandra P. Belani"'
Autor:
Madhusmita Behera, PhD, Renjian Jiang, MS, Zhonglu Huang, MS, Becky Bunn, MS, Murry W. Wynes, PhD, Jeffrey Switchenko, PhD, Giorgio V. Scagliotti, MD, Chandra P. Belani, MD, Suresh S. Ramalingam, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100592- (2024)
Introduction: EGFR exon 20 insertion (ex20ins) mutations account for approximately 10% of EGFR mutations in lung adenocarcinoma. Patients with ex20ins mutation do not respond to standard EGFR tyrosine kinase inhibitor therapy. In this work, we analyz
Externí odkaz:
https://doaj.org/article/f92ad290cb7e478fb92426609abe2a43
Autor:
Chan Shen, Rolfy A. Perez Holguin, Eric Schaefer, Shouhao Zhou, Chandra P. Belani, Patrick C. Ma, Michael F. Reed
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidel
Externí odkaz:
https://doaj.org/article/9156033407404c5fb98633827189670b
Autor:
Sarina Piha-Paul, MD, George Simon, MD, Chandra P. Belani, MD, Heman Chao, PhD, Kim Gaspar, PhD, Brenda Lee, MSc, Afshin Dowlati, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100408- (2022)
Introduction: L-DOS47, a targeted urease–anti-CEACAM6 immunoconjugate, alters the acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the cytotoxic effects of L-DOS47 were additive when combined with pemetrexed a
Externí odkaz:
https://doaj.org/article/b0e5a55630a34b9db3db56cd15ad246c
Autor:
Mengmeng Sang, Shawn Rice, Libo Jiang, Xin Liu, Claudia Gragnoli, Chandra P. Belani, Rongling Wu
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 18, Iss , Pp 45-51 (2020)
Intratumoral heterogeneity (ITH) has been regarded as a key cause of the failure and resistance of cancer therapy, but how it behaves and functions remains unclear. Advances in single-cell analysis have facilitated the collection of a massive amount
Externí odkaz:
https://doaj.org/article/1541533a8647428489aa4de2a421dd3c
Autor:
Monica K. Malhotra, Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin, Hussein A. Tawbi, Ronald G. Stoller, James J. Lee, Chandra P. Belani, Alice P. Chen, Vincent L. Giranda, Stacie Peacock Shepherd, Leisha A. Emens, S. Percy Ivy, Edward Chu, Jan H. Beumer, Shannon Puhalla
Publikováno v:
Breast Cancer Research and Treatment. 198:487-498
Autor:
Shawn J Rice, Chandra P Belani
Publikováno v:
PLoS ONE, Vol 16, Iss 12, p e0260988 (2021)
Blood-based biomarkers including systemic inflammation (SI) indicators or circulating factors (cytokines, chemokines, or growth factors) are associated with a poor prognosis for lung cancer patients. Collectively these biomarkers can predict the immu
Externí odkaz:
https://doaj.org/article/73f5cf2c0e2d4cfcaea1c952bc51f472
Autor:
Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela C. Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) res
Externí odkaz:
https://doaj.org/article/ca57b5df964545278ac1f00ea2e76a4d
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0217657 (2019)
Lung cancer is among the common and deadly cancers. Although the treatment options for late-stage cancer patients have continued to increase in numbers, the overall survival rates for these patients have not shown significant improvement. This highli
Externí odkaz:
https://doaj.org/article/a7ad9fd966d24fb9bb72eeadce9a3546
Autor:
Edward M. Newman, S. Percy Ivy, S. Cecilia Lau, Leena Gandhi, Chandra P. Belani, Daniel L. Mulkerin, Afshin Dowlati, Michelle A. Rudek, Patricia LoRusso, John Sarantopoulos, Bert H. O'Neil, Anne L. Hamilton, R. Donald Harvey, Shivaani Kummar, Heinz-Josef Lenz, Lone H. Ottesen, A. Benjamin Suttle, Jeffrey A. Longmate, Timothy W. Synold, Vincent Chung, Stephen I. Shibata
PDF - 90K, Supplemental Table 1: Most Frequently Reported Adverse Events at Least Possibly Related to Pazopanib Supplemental Table 2: Steady-State Pazopanib Metabolite Pharmacokinetics Measured in All Patients at Week 3 (medians and ranges) Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42d15641f7e868af03b66588542f389d
https://doi.org/10.1158/1078-0432.22452693.v1
https://doi.org/10.1158/1078-0432.22452693.v1
Autor:
Edward M. Newman, S. Percy Ivy, S. Cecilia Lau, Leena Gandhi, Chandra P. Belani, Daniel L. Mulkerin, Afshin Dowlati, Michelle A. Rudek, Patricia LoRusso, John Sarantopoulos, Bert H. O'Neil, Anne L. Hamilton, R. Donald Harvey, Shivaani Kummar, Heinz-Josef Lenz, Lone H. Ottesen, A. Benjamin Suttle, Jeffrey A. Longmate, Timothy W. Synold, Vincent Chung, Stephen I. Shibata
Purpose: Pazopanib is a potent, multitargeted receptor tyrosine kinase inhibitor; however, there is limited information regarding the effects of liver function on pazopanib metabolism and pharmacokinetics. The objective of this study was to establish
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d59996474bd83689123ac9fd61ea25
https://doi.org/10.1158/1078-0432.c.6522558
https://doi.org/10.1158/1078-0432.c.6522558